Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma

Rationale: The existence of primary and acquired drug resistance is the main obstacle for the effect of multi-kinase inhibitor sorafenib and regorafenib in advanced hepatocellular carcinoma (HCC). However, plenty of patients did not significantly benefit from sorafenib treatment and little is known...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Jing, Sui, Cheng-Jun, Wang, Dong-Fang, Lu, Xin-Yuan, Luo, Gui-Juan, Zhao, Qing, Lian, Qiu-Yu, Jeong, Seogsong, Lin, Xi-Meng, Zhu, Yan-Jing, Zheng, Bo, Wu, Rui, Wang, Qing, Liu, Xiao-Long, Liu, Jing-Feng, Xia, Qiang, Wu, Gang, Gu, Jin, Wang, Hong-Yang, Chen, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196302/
https://www.ncbi.nlm.nih.gov/pubmed/32373219
http://dx.doi.org/10.7150/thno.41616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196302/
https://www.ncbi.nlm.nih.gov/pubmed/32373219
http://dx.doi.org/10.7150/thno.41616

Ejemplares similares